Multiple agent diabetes therapy

• US 7,323,543 B2
• Filed: 06/24/2005
• Issued: 01/29/2008
• Est. Priority Date: 06/25/1999
• Status: Expired due to Term

• Current Assignee: Minimed, Inc. (Medtronic Plc)
• Original Assignee: Minimed, Inc. (Medtronic Plc)
• Inventors: Pfuetzner, Andreas H. R., Van Antwerp, William P.
• Primary Examiner(s): Lukton; David
• Application Number:
  US11/166,390
• Publication Number:
  US 20060074013A1
• Time in Patent Office: 949 Days
• Field of Search: 514/3, 514/4, 514/342, 514/12, 530/303, 530/304, 530/308
• US Class Current: 530/308
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

Claims

1. A method of treating diabetes comprising the step of administering to a patient in need of such treatment at least two pharmaceutical compositions (a)-(c), wherein:

composition (a) comprises;

(i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and

(ii) a pharmaceutically acceptable carrier,

composition (b) comprises;

(i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

(ii) a pharmaceutically acceptable carrier, and

composition (c) comprises;

(i) an insulin sensitizer, and

(ii) a pharmaceutically acceptable carrier,

and wherein compositions (b) and (c) are required and administered concomitantly and further wherein the compositions administered in the method comprise GLP-1, troglitazone and Genapol 1800.

2. The method of claim 1 wherein each of said compositions is administered to said patient using a separate delivery device.

3. The method of claim 2 wherein each said delivery device is a medication infusion pump.

4. The method of claim 1 wherein each of said compositions is administered at a different rate.

5. The method of claim 1 wherein each of said compositions is administered continually.

6. The method of claim 1 wherein compositions (b) and (c) are administered to said patient.

7. The method of claim 1 wherein compositions (a), (b) and (c) are administered to said patient.